Panellists in this video:
+ Dr Ashok Omray, Pharma Consultant (MODERATOR)
+ Dr Shubhadeep D Sinha, Sr VP, Head- Clinical Development & Medical Affairs, Hetero Labs
+ Dr Kamal Kumar Upadhyay, VP- Head R&D Pharma SGI, Biological E
+ Dr Vasanthakumar Ramu, VP – Head R&D – Peptides & Complex APIs, Alembic Pharmaceuticals
+ Mr Murali Jayaraman, Head – Formulation and Drug Product Development, Dr Reddy’s Laboratories
Key Highlights:
[1] Peptide-based products must rigorously adhere to regulations, ensuring safety, efficacy, and quality standards are consistently met.
[2] Accurate impurity profiling in peptides presents scientific and technical challenges that require innovative analytical strategies.
[3] The ultimate objective of biosimilar development should be to enhance patient outcomes through accessible, effective, and user-friendly therapies.
[4] Future biologics and biosimilars should prioritize self-administration capabilities, empowering patients and improving adherence.
[5] Ensuring the affordability and widespread availability of biosimilars remains a cornerstone for expanding patient access to advanced therapies.